-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
What is the current status of volume purchasing? Where will it go in the future?
The wind is rising! The cloud returns to the place, 2025 should be full!
The author has a copy of the Medical Economics News in February this year, which has been kept since
In this article, the author has a clear view and a clear attitude: "Scholars have proved that if sorted by purchase amount, 10% of large-variety drugs can account for 30% of total drug costs, and 30% of drugs can account for 50% or more.
In late June this year, Director Gong Bo of the Medical Service Department of the Shanghai Medical Insurance Bureau made it clear in an interview with News 1+1 that the national centralized procurement of 1-5 batches of 218 chemical drugs involved a total of 220 billion yuan, accounting for all the chemicals in public medical institutions.
Behind these seemingly boring articles and figures, the author understands that they are actually related or even influencing each other
500 is the first to put forward the concept of 500 catalogs in the industry after getting the exclusive news in July 2020
218 is the number of chemical medicines collected in five batches and six rounds so far
620, which belongs to the upgraded version of the new 500 catalog expansion version
490, not surprisingly, is the total amount of centralized procurement of chemical drugs purchased by the state
As for proprietary Chinese medicines and biosimilars, they basically fall into the range of 130 varieties (620-490)
At the Nanning meeting in May, relevant parties carried out a publicity and interpretation of Circular 2.
From this overall perspective, Hu Shanlian and other experts’ articles are actually a kind of early stage gathering and public opinion foreshadowing.
Going back to the article by Professor Hu Shanlian cited at the beginning of this article.
The last topic is about national talks
In the past two days, the "Response of the National Medical Security Administration to Recommendation No.
The medical insurance payment standards are currently being implemented, or some have been implemented but not all have been implemented
